Immunogenicity of Replication-deficient Vesicular Stomatitis Virus Based Rabies Vaccine in Mice

Overview

Journal Vet Q

Specialty Veterinary Medicine

Date 2021 May 14

PMID 33985418

Citations 3

Authors

Jung-Eun Park

Hyun-Jin Shin

Affiliations

Soon will be listed here.

Abstract

Background: Rabies is a viral disease that causes severe neurological manifestations both in humans and various mammals. Although inactivated and/or attenuated vaccines have been developed and widely used around the world, there are still concerns with regard to their safety, efficacy, and costs.

Objective: As demand has grown for a new rabies vaccine, we have developed a new vesicular stomatitis viruses (VSVs) based rabies vaccine that replaces glycoproteins with rabies virus (RABV) glycoprotein (GP), or so-called VSV/RABV-GP.

Methods: VSV/RABV-GP production was measured by sandwich ELISA. The generation of VSV/RABV-GP was evaluated with GP-specific antibodies and reduced transduction with GP-specific neutralizing antibodies. Virus entry was quantified by measuring the luciferase levels at 18-h post-transduction. BALB/c mice (three groups of six mice each) were intraperitoneally immunized with PBS, RABA, or VSV/RABV-GP at 0 and 14 days. At 28 days post-immunization serology was performed. Statistical significance was calculated using the Holm-Sidak multiple Student's test.

Results: Mice immunized with VSV/RABV-GP produced IgM and IgG antibodies, whereas IgM titers were significantly higher in mice immunized with VSV/RABV-GP compared to inactivated RABV. The secretion profiles of IgG1 and IgG2a production suggested that VSV/RAVB-GP induces the T helper cell type-2 immune bias. In addition, the average (±SD; = 3) serum neutralization titers of the inactivated RABV and VSV/RABV-GP groups were 241 ± 40 and 103 ± 54 IU/mL, respectively.

Conclusion: Our results confirm that VSV/RABV-GP could be a new potential vaccination platform for RABV.

Citing Articles

Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization.

Natesan K, Isloor S, Vinayagamurthy B, Ramakrishnaiah S, Doddamane R, Fooks A Vaccines (Basel). 2023; 11(4).

PMID: 37112668 PMC: 10147034. DOI: 10.3390/vaccines11040756.

A single dose of recombinant VSV-RABV vaccine provides full protection against RABV challenge.

Liang M, Wang Z, Wu C, Xiong S, Zhao L, Dong C Virol Sin. 2022; 37(3):455-458.

PMID: 35618603 PMC: 9243626. DOI: 10.1016/j.virs.2022.02.008.

Research Advances on the Interactions between Rabies Virus Structural Proteins and Host Target Cells: Accrued Knowledge from the Application of Reverse Genetics Systems.

Yin J, Wang X, Mao R, Zhang Z, Gao X, Luo Y Viruses. 2021; 13(11).

PMID: 34835093 PMC: 8617671. DOI: 10.3390/v13112288.

References

Cliquet F, Picard-Meyer E . Rabies and rabies-related viruses: a modern perspective on an ancient disease. Rev Sci Tech. 2005; 23(2):625-42. DOI: 10.20506/rst.23.2.1514. View

Wu F, Fan X, Yue Y, Xiong S, Dong C . A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine. 2014; 32(31):3917-26. PMC: 7115516. DOI: 10.1016/j.vaccine.2014.05.052. View

Nandi S, Kumar M . Development in Immunoprophylaxis against Rabies for Animals and Humans. Avicenna J Med Biotechnol. 2013; 2(1):3-21. PMC: 3558146. View

Diamond M, Sitati E, Friend L, Higgs S, Shrestha B, Engle M . A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med. 2003; 198(12):1853-62. PMC: 2194144. DOI: 10.1084/jem.20031223. View

Ramya R, Mohana Subramanian B, Sivakumar V, Senthilkumar R, Rao K, Srinivasan V . Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice. Clin Vaccine Immunol. 2011; 18(10):1673-9. PMC: 3187018. DOI: 10.1128/CVI.05258-11. View

Hangartner L, Zinkernagel R, Hengartner H . Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006; 6(3):231-43. DOI: 10.1038/nri1783. View

Park J, Li K, Barlan A, Fehr A, Perlman S, McCray Jr P . Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A. 2016; 113(43):12262-12267. PMC: 5086990. DOI: 10.1073/pnas.1608147113. View

Boes M, Esau C, Fischer M, Schmidt T, Carroll M, Chen J . Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol. 1998; 160(10):4776-87. View

Kamoltham T, Khawplod P, Wilde H . Rabies intradermal post-exposure vaccination of humans using reconstituted and stored vaccine. Vaccine. 2002; 20(27-28):3272-6. DOI: 10.1016/s0264-410x(02)00299-2. View

10.

Dorfmeier C, Shen S, Tzvetkov E, McGettigan J . Reinvestigating the role of IgM in rabies virus postexposure vaccination. J Virol. 2013; 87(16):9217-22. PMC: 3754079. DOI: 10.1128/JVI.00995-13. View

11.

Ertl H . New Rabies Vaccines for Use in Humans. Vaccines (Basel). 2019; 7(2). PMC: 6631309. DOI: 10.3390/vaccines7020054. View

12.

Cobleigh M, Bradfield C, Liu Y, Mehta A, Robek M . The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. J Virol. 2012; 86(8):4253-61. PMC: 3318607. DOI: 10.1128/JVI.05991-11. View

13.

Chen T, Zhou X, Qi Y, Mi L, Sun X, Zhang S . Feline herpesvirus vectored-rabies vaccine in cats: A dual protection. Vaccine. 2019; 37(16):2224-2231. DOI: 10.1016/j.vaccine.2019.03.008. View

14.

Rupprecht C, Nagarajan T, Ertl H . Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention. Expert Rev Vaccines. 2016; 15(6):731-49. DOI: 10.1586/14760584.2016.1140040. View

15.

Marzi A, Feldmann F, Geisbert T, Feldmann H, Safronetz D . Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis. 2015; 21(2):305-7. PMC: 4313664. DOI: 10.3201/eid2102.141649. View

16.

Flamand A, Raux H, Gaudin Y, Ruigrok R . Mechanisms of rabies virus neutralization. Virology. 1993; 194(1):302-13. DOI: 10.1006/viro.1993.1261. View

17.

Moore S, Hanlon C . Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS Negl Trop Dis. 2010; 4(3):e595. PMC: 2834733. DOI: 10.1371/journal.pntd.0000595. View

18.

Chulasugandha P, Khawplod P, Havanond P, Wilde H . Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine. 2005; 24(9):1478-82. DOI: 10.1016/j.vaccine.2005.03.059. View

19.

Tober R, Banki Z, Egerer L, Muik A, Behmuller S, Kreppel F . VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol. 2014; 88(9):4897-907. PMC: 3993835. DOI: 10.1128/JVI.03276-13. View

20.

Wang C, Dulal P, Zhou X, Xiang Z, Goharriz H, Banyard A . A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Negl Trop Dis. 2018; 12(10):e0006870. PMC: 6224154. DOI: 10.1371/journal.pntd.0006870. View